The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Lipid Formulations of Amphotericin B: Clinical Efficacy and Toxicities
Abstract
Commercially available lipid formulations of amphotericin B (Abelcet, Amphotec, and AmBisome) represent a significant advance in drug delivery technology. Differences in biochemical, pharmacokinetic, and pharmacodynamic properties among the lipid products have been shown in in vitro and in vivo models. Clinical experience with these products has been primarily in patients either refractory to or intolerant of conventional amphotericin B deoxycholate (AmBd). None of the lipid-based products demonstrates superior efficacy when prospectively compared with AmBd in the treatment of documented infections. When used for the empirical treatment of febrile neutropenia, AmBisome significantly reduced the incidence of proven emergent fungal infections but did not improve short-term survival rates, in comparison with AmBd. Acute infusion-related adverse events vary, whereas nephrotoxicity is reduced with all three lipid formulations. Until superior efficacy is clearly shown (for documented infections) or pharmacoeconomic analyses document the value of these drugs, use of such expensive agents should be highly restricted to those who are intolerant of or refractory to AmBd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prentice, H. G., Hann, I. M., Herbrecht, R., Aoun, M., Kvaloy, S., Catovsky, D., Pinkerton, C. R., Schey, S. A., Jacobs, F., Oakhill, A., et al. (1997) · British Journal of Haematology · doi:10.1046/j.1365-2141.1997.2473063.x · Cited by 439
Lopez-Berestein, G., Fainstein, V., Hopfer, R., Mehta, K., Sullivan, M. P., Keating, M., Rosenblum, M. G., Mehta, R., Luna, M., Hersh, E. M., et al. (1985) · Journal of Infectious Diseases · doi:10.1093/infdis/151.4.704 · Cited by 405
Lipid Formulations of Amphotericin B: Recent Progress and Future Directions
Hiemenz, J. W., & Walsh, T. J. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.supplement_2.s133 · Cited by 404
Ringden, O., Meunier, F., Tollemar, J., Ricci, P., Tura, S., Kuse, E., Viviani, M. A., Gorin, N. C., Klastersky, J., Fenaux, P., et al. (1991) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/28.suppl_b.73 · Cited by 280
Liposomal and Lipid Formulations of Amphotericin B: Clinical Pharmacokinetics
Janknegt, R., de Marie, S., Bakker-Woudenberg, I. A. J. M., & Crommelin, D. J. A. (1992) · Clinical Pharmacokinetics · doi:10.2165/00003088-199223040-00004 · Cited by 274
Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial
Meunier, F., Prentice, H. G., & Ringden, O. (1991) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/28.suppl_b.83 · Cited by 247
Distribution and Activity of Amphotericin B in Humans
Christiansen, K. J., Bernard, E. M., Gold, J. W. M., & Armstrong, D. (1985) · Journal of Infectious Diseases · doi:10.1093/infdis/152.5.1037 · Cited by 229
Unusual lipid structures selectively reduce the toxicity of amphotericin B.
Janoff, A. S., Boni, L. T., Popescu, M. C., Minchey, S. R., Cullis, P. R., Madden, T. D., Taraschi, T., Gruner, S. M., Shyamsunder, E., & Tate, M. W. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.16.6122 · Cited by 223
Chemotherapy of Systemic Mycoses
Bennett, J. E. (1974) · New England Journal of Medicine · doi:10.1056/nejm197401032900107 · Cited by 220
Treatment of hepatosplenic candidiasis with liposomal-amphotericin B.
Lopez-Berestein, G., Bodey, G. P., Frankel, L. S., & Mehta, K. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.2.310 · Cited by 216
Cited by
Walsh, T. J., Pappas, P., Winston, D. J., Lazarus, H. M., Petersen, F., Raffalli, J., Yanovich, S., Stiff, P., Greenberg, R., Donowitz, G., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejm200201243460403 · Cited by 979
Amphotericin B formulations: a comparative review of efficacy and toxicity
Hamill, R. J. (2013) · Drugs · doi:10.1007/s40265-013-0069-4 · Cited by 807
Mehta, M., Bui, T. A., Yang, X., Aksoy, Y., Goldys, E. M., & Deng, W. (2023) · ACS Materials Au · doi:10.1021/acsmaterialsau.3c00032 · Cited by 688
Wingard, J. R., White, M. H., Anaissie, E., Raffalli, J., Goodman, J., Arrieta, A., & L Amph/ABLC Collaborative Study Group (2000) · Clinical Infectious Diseases · doi:10.1086/317451 · Cited by 527
Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients
Bellmann, R., & Smuszkiewicz, P. (2017) · Infection · doi:10.1007/s15010-017-1042-z · Cited by 389
Metadata
- Authors
- Wong-Beringer, A., Jacobs, R. A., & Guglielmo, B. J.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 1998-09-01
- Volume
- 27
- Issue
- 3
- Pages
- 603-618
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W1978263354
- Cited by
- 395
- References
- 46
- FWCI
- 20.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lipid Formulations of Amphotericin B: Clinical Efficacy and Toxicities. https://app.cochat.ai/papers/10.1086/514704
- The paper
- Wong-Beringer, A., Jacobs, R. A., & Guglielmo, B. J. (1998). Lipid Formulations of Amphotericin B: Clinical Efficacy and Toxicities. Clinical Infectious Diseases. https://doi.org/10.1086/514704
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
